Lung Cancer Diagnosis: Tests, Procedures, and What to Expect

Key Takeaways

• Imaging (chest X-ray, CT, PET, possibly MRI) detects suspicious lesions, but biopsy is required to confirm lung cancer diagnosis and determine cell type.

• Biomarker testing identifies specific mutations and protein markers (EGFR, ALK, ROS1, PD-L1, KRAS G12C, BRAF, RET, MET, NTRK) that determine eligibility for targeted therapy and immunotherapy drugs.

• Next-generation sequencing panels provide comprehensive molecular profiling in a single test, revealing all relevant mutations and guiding personalized treatment selection.

• Staging determines cancer extent (localized vs. regional vs. metastatic spread) and is essential for prognosis, treatment planning, and clinical trial eligibility.

• The diagnostic process typically takes 1-3 weeks and involves multiple steps; bringing support, asking questions, and seeking emotional help are all appropriate and encouraged.

• Your diagnostic results directly determine clinical trial eligibility — comprehensive testing opens more trial options and increases chances of accessing cutting-edge treatments.

Introduction

A lung cancer diagnosis begins the moment abnormal cells are detected in your lungs and confirmed through testing. According to the National Cancer Institute, receiving a prompt and thorough diagnosis is the foundation for developing an effective treatment plan tailored to your specific cancer type, stage, and molecular characteristics. The diagnostic process typically involves multiple imaging studies, tissue sampling, and laboratory tests that work together to provide your medical team with the complete picture needed to guide your care.

It’s completely normal for the diagnostic journey to feel overwhelming. Understanding what to expect during each step, from your first imaging scan to biomarker test results, can help you feel more prepared and empowered as you move forward with your treatment planning.

This guide walks you through every component of the lung cancer diagnostic process. We'll explain what each test reveals, why your doctors order them, what the procedures feel like, and how your results directly influence your eligibility for clinical trials that may offer access to cutting-edge treatments.

Initial Evaluation and Imaging

Chest X-ray

A chest X-ray is often the first imaging test ordered when lung cancer is suspected. This simple, non-invasive test uses low-dose radiation to create images of your lungs and chest cavity. According to the American College of Radiology, a chest X-ray can reveal suspicious masses, nodules, or areas of consolidation that may warrant further investigation.

A standard chest X-ray takes only a few minutes. You'll stand in front of the X-ray machine and hold your breath briefly while the image is captured. The procedure is painless, involves minimal radiation exposure, and results are typically available within hours. However, a chest X-ray alone cannot provide enough detail to confirm a cancer diagnosis. Additional imaging is almost always needed when something is seen on X-ray.

CT Scan (Computed Tomography)

A CT scan is far more detailed than a chest X-ray and is essential for evaluating lung lesions. This imaging technique takes multiple cross-sectional images of your chest, creating a three-dimensional picture that shows the size, location, and characteristics of any abnormal areas. According to the American Cancer Society, CT imaging can detect nodules smaller than 1 centimeter and help determine whether cancer may have spread to lymph nodes or other structures.

A CT scan typically takes 10-30 minutes. You'll lie still on a table that slides through a large, ring-shaped scanner. The machine may make clicking or whirring sounds. Some patients receive IV contrast (a dye) injected before or during the scan to enhance image clarity. The contrast helps distinguish blood vessels and different tissue types. If you have a contrast allergy or kidney disease, inform your medical team beforehand. The scan is painless, though some patients experience brief claustrophobia in the enclosed space.

PET Scan (Positron Emission Tomography)

A PET scan detects metabolic activity, which is how quickly cells are using glucose (sugar). Cancer cells typically consume glucose more rapidly than normal cells, making them appear as "hot spots" on PET imaging. According to the National Institutes of Health, PET scans are valuable for confirming whether nodules seen on CT are cancerous and for detecting whether cancer has spread to distant organs.

Before a PET scan, you'll receive an injection of a radioactive glucose tracer. You'll wait 30-60 minutes while the tracer circulates through your body, then lie still in the PET scanner for 20-30 minutes. The procedure is painless. The radiation exposure is minimal and washes out of your system naturally within hours. PET scans are often combined with CT imaging (PET-CT) for simultaneous anatomical and metabolic information.

MRI (Magnetic Resonance Imaging)

While CT and PET scans are the primary imaging tools for lung cancer diagnosis and staging, MRI may be ordered in specific situations. MRI uses magnetic fields and radio waves to create detailed images and is particularly valuable for detecting metastatic spread to the brain. According to the American Academy of Neurology, brain MRI is routinely recommended for patients with advanced lung cancer because the brain is a common site of metastasis.

An MRI scan takes 30-60 minutes. You'll lie inside a long, tube-shaped machine and remain very still. The machine produces loud banging noises. Unlike CT, MRI involves no radiation. However, if you have metal implants (pacemakers, metal plates, or certain aneurysm clips), inform your medical team as these may contraindicate MRI.

Biopsy Procedures

A biopsy is the removal and microscopic examination of tissue to confirm the presence of cancer cells, determine the specific type of lung cancer, and identify molecular characteristics. A diagnosis of lung cancer cannot be confirmed without a biopsy. Several approaches are available, depending on the size and location of the suspicious area.

Bronchoscopy

A bronchoscopy allows your pulmonologist to directly visualize the airways inside your lungs using a thin, flexible tube (bronchoscope) equipped with a camera and light. If the suspicious area is accessible through the airways, the doctor can obtain tissue samples or brush samples directly from the lesion.

During a bronchoscopy, you'll receive sedation to help you relax (you'll be drowsy but not fully asleep). Your throat will be numbed with a local anesthetic spray. The bronchoscope, a long, thin, flexible instrument with a light and camera, is gently passed through your mouth or nose, down your windpipe, and into your lungs. The procedure typically takes 20-40 minutes. You may feel mild pressure or hear suction sounds. After the procedure, your throat may feel slightly sore for a few hours, and you may cough up small amounts of blood-tinged sputum — this is normal. You'll need someone to drive you home due to sedation.

CT-Guided Needle Biopsy

For lesions located in the lung periphery (away from airways), a CT-guided needle biopsy is often the preferred approach. Real-time CT imaging guides a thin needle directly to the suspicious area. Your radiologist or pulmonologist advances the needle, obtains tissue samples, and withdraws.

You'll lie on a CT scanner table, and the radiologist will mark the needle path using CT imaging. Local anesthetic is injected into the skin. You'll feel pressure as the needle advances but minimal pain. The entire procedure takes 15-30 minutes. Afterward, a chest X-ray confirms there are no complications (such as a small collapsed lung section). Most patients go home the same day. Some mild chest wall soreness is normal and resolves within a few days.

Thoracentesis

If fluid accumulates around your lungs (pleural effusion), thoracentesis allows your doctor to sample this fluid for cancer cells while simultaneously relieving lung compression and breathing difficulty. A needle is inserted between your ribs into the fluid collection space.

You'll sit upright on the edge of a bed. Local anesthetic numbs the skin, and the needle is carefully inserted. You'll feel pressure and brief stinging as the needle passes through the tissue. The procedure takes 10-20 minutes. Afterward, a chest X-ray confirms proper lung re-expansion. Most patients experience improved breathing immediately after fluid removal.

Mediastinoscopy

The mediastinum is the central chest compartment containing the heart and major blood vessels. Mediastinal lymph nodes often become involved in lung cancer. Mediastinoscopy is a surgical procedure allowing direct visualization and sampling of these nodes when less invasive methods are inconclusive.

Mediastinoscopy is performed in an operating room under general anesthesia. A small incision is made above the breastbone, and a mediastinoscope (similar to a bronchoscope but larger) is advanced into the mediastinum. Lymph node samples are obtained. The procedure takes 30-60 minutes. You'll spend several hours in recovery and typically go home the same day or stay overnight. Minimal post-operative discomfort is expected.

Surgical Biopsy

In some cases, open surgical biopsy (thoracotomy) or video-assisted thoracoscopic surgery (VATS) may be necessary to obtain adequate tissue, particularly if the lesion is difficult to access or previous biopsy attempts were non-diagnostic. These procedures are performed under general anesthesia in an operating room.

Thoracotomy involves a larger surgical incision; VATS uses several small incisions and video guidance, resulting in less trauma. Both procedures allow direct visualization and removal of tissue or even an entire nodule. Recovery takes 2-4 weeks. Hospital stay is typically 1-2 days. Post-operative pain is managed with medications.

Biomarker and Molecular Testing

Once tissue is obtained through biopsy, comprehensive molecular testing is absolutely essential. According to the National Comprehensive Cancer Network, biomarker testing should be performed on all patients with advanced non-small cell lung cancer (NSCLC) because specific molecular mutations and protein markers determine eligibility for targeted therapy and immunotherapy drugs that may dramatically improve survival.

Why Biomarker Testing Matters

Traditional cancer classification focused on histology (cell type: adenocarcinoma, squamous cell carcinoma, large cell carcinoma) and stage. Today, we know that two cancers of identical histology and stage may behave completely differently and respond to different treatments based on their underlying molecular makeup. Biomarker testing reveals this molecular "fingerprint."

Key Biomarkers and What They Mean 

According to a comprehensive 2021 review of oncogenic driver mutations in NSCLC published in the World Journal of Clinical Oncology, targeted mutations are present across a wide range of frequencies — with EGFR being the most common actionable mutation in non-squamous NSCLC in Western populations, and rarer alterations like NTRK affecting less than 1% of patients but still qualifying for approved targeted therapies.

EGFR (Epidermal Growth Factor Receptor): Found in approximately 15–20% of non-small cell lung cancers — more commonly in never-smokers and patients of Asian descent. Responsive to targeted drugs including erlotinib, gefitinib, and the third-generation agent osimertinib.

ALK (Anaplastic Lymphoma Kinase): Occurs in approximately 3–5% of NSCLCs, most often in younger patients with a non-smoking history. Responds dramatically to ALK inhibitors such as crizotinib, alectinib, and brigatinib.

ROS1 (ROS Proto-Oncogene 1): Found in 1–2% of NSCLCs. Sensitive to crizotinib and newer-generation ROS1-targeted inhibitors.

PD-L1 (Programmed Death-Ligand 1): A protein expressed on cancer cell surfaces that helps determine immunotherapy eligibility. Higher expression generally correlates with better response to checkpoint inhibitor drugs.

KRAS G12C: Once considered undruggable, this mutation is now targetable with FDA-approved agents sotorasib and adagrasib. According to a 2023 review in the journal Lung Cancer, KRAS G12C is present in approximately 13% of NSCLCs, particularly in current and former smokers.

BRAF: Present in approximately 2–3% of lung cancers. BRAF V600E-mutant tumors respond to BRAF inhibitors such as vemurafenib and dabrafenib, typically combined with MEK inhibitors.

RET: Found in 1–2% of NSCLCs. Responds to the RET inhibitors selpercatinib and pralsetinib, both FDA-approved for RET fusion-positive NSCLC.

MET: MET exon 14 skipping mutations occur in 3–4% of NSCLCs and are sensitive to MET inhibitors including capmatinib and tepotinib.

NTRK: Rare in lung cancer — present in less than 1% of cases — but highly sensitive to NTRK inhibitors larotrectinib and entrectinib regardless of tumor type.

Next-Generation Sequencing and Comprehensive Panels

Rather than testing for individual mutations one at a time, most centers now use next-generation sequencing (NGS) panels that simultaneously analyze hundreds of genes in a single test. These comprehensive panels identify not just the major "druggable" mutations listed above, but also secondary mutations, tumor mutational burden, and other markers relevant to treatment selection and clinical trial eligibility.

NGS results typically take 7-14 days. Once results are available, your oncology team reviews them in the context of your clinical presentation to recommend the most appropriate treatment options. Many patients discover they have specific molecular features making them eligible for targeted therapies or clinical trials offering novel drugs not yet broadly available.

Staging After Diagnosis

Staging determines the extent of cancer spread and is essential for prognosis and treatment planning. Lung cancer staging uses the TNM system: T (tumor size and local invasion), N (lymph node involvement), and M (distant metastatic spread).

Stage I cancers are localized to the lung with no lymph node involvement and no metastases. Stage II involves larger tumors or lymph node involvement. Stage III cancers involve extensive local and regional spread. Stage IV (metastatic) cancers have spread to distant organs (brain, bones, liver, adrenal glands).

Your staging workup typically includes:

• Chest and abdomen CT scan to evaluate local tumor extent, regional lymph nodes, and liver/adrenal involvement

• Brain MRI to screen for brain metastases (standard for Stage III and IV)

• Bone scan or PET-CT if bone metastases are suspected

• Possibly additional imaging if symptoms suggest specific organ involvement

For more detailed information about each stage and what it means for prognosis and treatment, visit our comprehensive Lung Cancer Stages guide.

What to Expect During the Diagnostic Process

Timeline and Realistic Expectations

The diagnostic process typically unfolds over 1-3 weeks, though individual timelines vary. Your first visit might include imaging and initial assessment. Biopsy procedures may be scheduled within days or a week. Pathology analysis takes several days. Biomarker testing takes 7-14 days. Once all results are available, your oncologist schedules a results discussion and treatment planning appointment.

Understanding this timeline helps reduce anxiety. You may experience frustration with waiting periods, but each step — imaging confirmation, tissue diagnosis, molecular profiling — is essential for optimal treatment selection.

Emotional Support During Diagnosis

The diagnostic period is emotionally challenging. You're processing uncertainty, fear, and potentially devastating news. It's completely normal to feel anxiety, anger, sadness, or numbness. Consider:

• Bringing a trusted friend or family member to appointments. They can take notes, ask questions, and provide emotional support.

• Asking your medical team to repeat or clarify information. You don't need to understand everything immediately.

• Requesting mental health support. Many cancer centers offer counseling, support groups, and psychiatric services.

• Connecting with other lung cancer patients. Peer support from those who've walked this path can be invaluable.

• Taking breaks from medical information when needed. Balance learning with self-care.

Questions to Ask Your Doctor

During your diagnostic visits, consider asking:

• "What does my imaging show, and what are we looking for with the biopsy?"

• "Why are we doing these specific tests in this order?"

• "When will I have results, and how will you share them?"

• "What does my pathology report tell us about my cancer type?"

• "What biomarker testing are you doing, and why does each one matter?"

• "Based on my stage and molecular features, what treatment options are most likely?"

• "Am I eligible for any clinical trials, and how do I learn more?"

• "What questions should I bring to my oncology consultation?"

Your medical team should welcome these questions. Understanding your diagnosis empowers you to participate actively in treatment decisions.

How Diagnosis Connects to Clinical Trial Eligibility

Your diagnostic results — particularly your stage, histology, and biomarker profile — directly determine your eligibility for clinical trials offering novel treatments, combination therapies, and cutting-edge approaches.

Biomarkers Open Trial Doors

If your testing reveals an EGFR mutation, you may be eligible for trials testing next-generation EGFR inhibitors designed to overcome resistance mechanisms. ALK-positive or ROS1-positive patients have access to trials exploring next-gen ALK/ROS1 inhibitors. KRAS G12C-mutant patients can explore trials combining G12C inhibitors with immunotherapy or other agents. PD-L1-positive patients may qualify for immunotherapy trials. Comprehensive biomarker testing reveals all potential trial matches.

Stage Determines Trial Options

Early-stage (I-II) lung cancer trials may test adjuvant (post-surgery) immunotherapy or targeted therapy. Advanced (III-IV) trials explore systemic chemotherapy, targeted therapy, immunotherapy, or combination approaches. Metastatic-specific trials evaluate treatments for specific metastatic sites (brain metastases, oligometastatic disease).

Comprehensive Testing Opens More Possibilities

Patients who receive thorough diagnostic testing including comprehensive molecular panels discover more trial options than those with limited biomarker assessment. The more your medical team understands your cancer's molecular profile, the more precisely they can match you with trials offering the best potential benefit.

Asking About Trials at Diagnosis

Many patients don't realize that clinical trial options should be discussed during the diagnostic and treatment planning phase, not months into treatment. At your results discussion appointment, explicitly ask your oncologist: "Am I eligible for any clinical trials? If so, what are my options, and what does participation involve?"

Our trial finder can help you identify studies for which you may be eligible based on your diagnosis, stage, location, and other factors. Visit our Lung Cancer Clinical Trials page to begin exploring options. Many patients find that trials offer access to innovative treatments unavailable outside research settings.

Frequently Asked Questions

How long does the diagnostic process typically take?

Most patients receive a complete diagnosis — including imaging, biopsy, pathology analysis, and biomarker testing — within 1-3 weeks. Some results (pathology) may be available within days; others (especially comprehensive molecular panels) take 7-14 days. Your oncology team can provide a more specific timeline based on your situation.

Will the biopsy hurt?

Modern biopsy procedures use local anesthesia to numb the area, and most patients experience minimal pain — typically pressure or mild discomfort rather than sharp pain. Bronchoscopy and needle biopsy are well-tolerated with sedation. Afterward, mild soreness is common but resolves quickly. Your medical team will discuss pain management and what to expect during your specific procedure.

What if my biomarker testing doesn't show a mutation?

Not all lung cancers have targetable mutations. If your testing shows wildtype (no specific mutations), you may be eligible for immunotherapy or traditional chemotherapy, and there are still clinical trials available that might be appropriate. Discuss with your oncologist what results mean for your treatment options and trial eligibility.

Do I need a brain MRI if I have no symptoms?

Yes, asymptomatic brain MRI screening is standard for Stage III and IV lung cancer patients because the brain is a common site of metastasis that may be present without causing symptoms. Early detection of brain metastases can guide treatment selection. Your oncologist will determine if brain imaging is appropriate based on your stage and risk factors.

How do my diagnostic results affect clinical trial eligibility?

Your stage, histology, and especially your biomarker profile determine which clinical trials are available to you. Patients with specific mutations (EGFR, ALK, ROS1, KRAS G12C) often have many trial options testing targeted agents. PD-L1-positive patients have immunotherapy trials. Comprehensive testing reveals all potential matches. Ask your oncologist to review trial options specific to your molecular profile.

Ready to explore clinical trials that may be right for you? Start your search with North's trial finder. Your diagnostic results are the foundation for finding the most appropriate and promising treatment options. Your medical team can help match your specific stage, histology, and biomarker profile with trials offering access to innovative therapies designed for patients exactly like you.

References

1. National Cancer Institute. "Lung Cancer — Patient Version." cancer.gov.

2. American Cancer Society. "Lung Cancer." cancer.org.

3. National Comprehensive Cancer Network. "NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, Version 3.2026." nccn.org.

4. Ettinger DS, Wood DE, Aisner DL, et al. "NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023." Journal of the National Comprehensive Cancer Network. 2023;21(4):340–350.

5. GO2 for Lung Cancer. "Biomarker Testing." go2.org.

6. American College of Radiology. "ACR Appropriateness Criteria." acr.org.

7. Chevallier M, Borgeaud M, Addeo A, Friedlaender A. "Oncogenic Driver Mutations in Non-Small Cell Lung Cancer: Past, Present and Future." World Journal of Clinical Oncology. 2021;12(4):217–237.

8. Lim TKH, Skoulidis F, Kerr KM, et al. "KRAS G12C in Advanced NSCLC: Prevalence, Co-Mutations, and Testing." Lung Cancer. 2023;184:107293.